Gordana Derado

Centers for Disease Control and Prevention — United States

Medicine · Health Sciences

33h-index5.2kcitations86works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antifungal resistance and susceptibility(20), Fungal Infections and Studies(19), SARS-CoV-2 and COVID-19 Research(11), Functional Brain Connectivity Studies(9), Viral gastroenteritis research and epidemiology(8)

Publications86 total

Estimated Burden of COVID-19 Illnesses, Medical Visits, Hospitalizations, and Deaths in the US From October 2022 to September 2024
JAMA Internal Medicine·2026· 2 citedOpen Access
P-696. Rapid estimates of RSV disease burden in the United States
Open Forum Infectious Diseases·2026Open Access
P-675. Chronic Conditions as Risk Factors for Respiratory Syncytial Virus-Associated Hospitalization among Community-Dwelling Adults Aged 18-49 Years, 2016-2017 and 2017-2018 Seasons
Open Forum Infectious Diseases·2026Open Access
Chronic Conditions as Risk Factors for COVID-19–Associated Hospitalization Among Adults, 2020–2023
American Journal of Preventive Medicine·2025Open Access
Letter to the Editor in Response to Zhao et al
The Journal of Infectious Diseases·2025
Respiratory Virus Detection and Acute Respiratory Illness Rates in Students and Staff in Schools
PEDIATRICS·2025· 1 cited
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged ≥65 Years in Long-Term Care
The Journal of Infectious Diseases·2025· 2 cited
The epidemiology of bacterial meningitis in the United States during 2008–2023: an analysis of active, laboratory, population-based, multistate surveillance data
The Lancet Regional Health - Americas·2025· 6 citedOpen Access
The Epidemiology and Burden of Human Parainfluenza Virus Hospitalizations in US Children
Journal of the Pediatric Infectious Diseases Society·2025
P-2008. Chronic Conditions as Risk Factors for COVID-19–Associated Hospitalization Among Adults, 2022-2023
Open Forum Infectious Diseases·2025Open Access
P-715. Chronic Conditions as Risk Factors for Respiratory Syncytial Virus-Associated Hospitalization among Community-Dwelling Adults Aged ≥50 Years, 2017 to 2018
Open Forum Infectious Diseases·2025· 1 citedOpen Access
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024
JAMA Pediatrics·2024· 43 citedOpen Access
Factors Associated with Legionella Detection in the Water Systems of National Lodging Organization Facilities with Water Management Programs in the United States
International Journal of Environmental Research and Public Health·2024· 1 citedOpen Access
Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods
Open Forum Infectious Diseases·2023· 12 citedOpen Access
Neuroimaging statistical approaches for determining neural correlates of Alzheimer's disease via positron emission tomography imaging
Wiley Interdisciplinary Reviews Computational Statistics·2023· 5 citedOpen Access
Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023
MMWR Morbidity and Mortality Weekly Report·2023· 22 citedOpen Access
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023
MMWR Morbidity and Mortality Weekly Report·2023· 144 citedOpen Access
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022
MMWR Morbidity and Mortality Weekly Report·2022· 185 citedOpen Access
Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
New England Journal of Medicine·2022· 54 citedOpen Access
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance
JAMA·2022· 159 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Nong Shang(11), Jennifer R. Verani(11), Amadea Britton(9), Emma K. Accorsi(8), Katherine E. Fleming-Dutra(8), Zachary Smith(8), Ruth Link‐Gelles(8), Stephanie J. Schrag(7), Joseph D. Miller(6), Shawn R. Lockhart(6), Tom Chiller(6), Kaitlin Benedict(6), Tamara Pilishvili(5), Eric D. Mintz(5), Snigdha Vallabhaneni(4), Allison Avrich Ciesla(4), Ryan E. Wiegand(4), Brendan R. Jackson(4), F. DuBois Bowman(4), Angela A. Cleveland(3)